NCT07649135 Feasibility of a Remotely Delivered Step Count Intervention in Chronic Stroke
| NCT ID | NCT07649135 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Minnesota |
| Condition | Stroke |
| Study Type | INTERVENTIONAL |
| Enrollment | 24 participants |
| Start Date | 2026-07-08 |
| Primary Completion | 2026-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 24 participants in total. It began in 2026-07-08 with a primary completion date of 2026-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to explore the feasibility of a new approach to rehabilitation that focuses on step count. Participants will complete 6 telephone or Zoom-based sessions with an occupational therapist over 6 weeks and use a step count tracker during that time. They will also complete questionnaires, assessments, surveys, and physical activity measurements during study weeks 0 (baseline), 3 (mid-point), 7 (post-intervention) and 12 (follow-up).
Eligibility Criteria
Inclusion Criteria: * Stroke diagnosis confirmed by imaging * Stroke occurred 6 or more months before study enrollment * Meet criteria for "inactive" on the International Physical Activity Questionnaire-Short Form * Able to identify a support person that they interact with in-person at least once per week * Able and willing to participate fully in the study and provide informed consent or proxy consent with participant assent Exclusion Criteria: * Currently receiving care in a transitional care unit, skilled nursing facility, or other institutional care setting * Currently receiving outpatient neurorehabilitation services (e.g., physical therapy, occupational therapy, speech therapy) * Severe cognitive or communication impairments (inability to respond accurately to complete study screening questions or to provide informed consent or assent) * Currently pregnant or expecting to become pregnant in the next 8 weeks Comorbid neurological disorder (Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, myasthenia gravis, dementia, Alzheimer's disease, Huntington's disease, glioblastoma, spinal cord injury, cerebral palsy) * Comorbid cancer, currently undergoing chemotherapy or radiation treatment * Received inpatient treatment or was hospitalized for a psychiatric condition and/or alcohol or substance abuse within the past 12 months * Current diagnosis of a terminal illness and/or currently receiving hospice care * History of allergic reaction to adhesives that precludes the use of an adhesive necessary for adherence to activPAL measurement * Uses wheelchair as primary mobility aid outside of home setting * Inability to speak, read, or understand English * Concurrent participation in another rehabilitation intervention research study * Resides more than 50 miles outside of the Twin Cities, Minnesota metropolitan area * Investigator discretion for safety or adherence reasons
Contact & Investigator
Emily Kringle, PhD, OTR/L
PRINCIPAL INVESTIGATOR
University of Minnesota
Frequently Asked Questions
Who can join the NCT07649135 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07649135 currently recruiting?
Yes, NCT07649135 is actively recruiting participants. Contact the research team at dwell@umn.edu for enrollment information.
Where is the NCT07649135 trial being conducted?
This trial is being conducted at Minneapolis, United States.
Who is sponsoring the NCT07649135 clinical trial?
NCT07649135 is sponsored by University of Minnesota. The principal investigator is Emily Kringle, PhD, OTR/L at University of Minnesota. The trial plans to enroll 24 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.